Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Acute Myeloid Leukemia
Related studies linked through entity extraction aliases.
Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- N/A
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE2
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
- Status
- COMPLETED
- Phase
- PHASE2
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE1
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
- Status
- TERMINATED
- Phase
- PHASE2
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
- Status
- COMPLETED
- Phase
- PHASE3
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Psychological Intervention Mobile App for Patients With AML
- Status
- COMPLETED
- Phase
- NA
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
- Status
- UNKNOWN
- Phase
- PHASE2
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.
- Status
- COMPLETED
- Phase
- N/A
MG4101 for Refractory or Relapsed AML
- Status
- COMPLETED
- Phase
- PHASE2
Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Status
- COMPLETED
- Phase
- PHASE2
Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission
- Status
- UNKNOWN
- Phase
- N/A
Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers
- Status
- UNKNOWN
- Phase
- NA
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
- Status
- TERMINATED
- Phase
- PHASE2